title: Appropriateness of the Zucker Diabetic Fatty rat as a model for diabetic microvascular late complications.
abstract: Male obese Zucker Diabetic Fatty (ZDF) rats develop type 2 diabetes around eight weeks of age, and are widely used as a model for human diabetes and its complications. The objective of the study was to test whether the complications manifested in the kidney and nerves of ZDF rats really correspond to human diabetic complications in their being related to the hyperglycaemic state. Four groups of ZDF rats were used. One lean (Fa/?) and one obese (fa/fa) untreated group served as non-diabetic and diabetic controls. In two further groups of obese (fa/fa) rats, diabetes was prevented by pioglitazone or delayed by food restriction. All rats were monitored up to 35 weeks of age with respect to their blood glucose, HbA1c and insulin levels, their kidney function (urinary glucose excretion, renal glucose filtration, glomerular filtration rate, albumin/creatinine ratio), and their nerve function (tactile and thermal sensory threshold and nerve conduction velocity). Pioglitazone prevented the development of diabetes, while food restriction delayed its onset for 8-10 weeks. Accordingly, kidney function parameters were similar to lean non-diabetic rats in pioglitazone-treated rats and significantly improved in food-restricted rats compared with obese controls. Kidney histology paralleled the functional results. By contrast, nerve functional evaluations did not mirror the differing blood glucose levels. We conclude that the ZDF rat is a good model for diabetic nephropathy, while alterations in nerve functions were not diabetes-related.
authors.affiliation: Diabetes Division, Translational Medicine, Sanofi-Aventis Deutschland GmbH, Industriepark Hoechst, H821, 65926 Frankfurt am Main, Germany.
authors.forename: J
authors.initials: J
authors.lastname: Hempe
authors.forename: R
authors.initials: R
authors.lastname: Elvert
authors.forename: H-L
authors.initials: HL
authors.lastname: Schmidts
authors.forename: W
authors.initials: W
authors.lastname: Kramer
authors.forename: A W
authors.initials: AW
authors.lastname: Herling
mesh_terms: D000818:Animals; D001774:Blood Chemical Analysis; D031204:Caloric Restriction; D003924:Diabetes Mellitus, Type 2 / Q000150:complications* / Q000188:drug therapy; D003928:Diabetic Nephropathies / Q000188:drug therapy / Q000209:etiology*; D003929:Diabetic Neuropathies / Q000188:drug therapy / Q000209:etiology*; D004195:Disease Models, Animal; D004797:Enzyme-Linked Immunosorbent Assay; D006801:Humans; D006943:Hyperglycemia / Q000150:complications / Q000188:drug therapy; D007004:Hypoglycemic Agents / Q000008:administration & dosage; D007668:Kidney / Q000473:pathology; D007677:Kidney Function Tests; D008297:Male; D009431:Neural Conduction; D000077205:Pioglitazone; D051381:Rats; D011924:Rats, Zucker; D012684:Sensory Thresholds; D045162:Thiazolidinediones / Q000008:administration & dosage
chemical_list: D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D000077205:Pioglitazone